Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-198-5 | CAS number: 13684-56-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: dermal
Administrative data
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1990-10-25 to 1991-03-26
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 991
- Report date:
- 1991
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
Test material
- Reference substance name:
- Desmedipham
- EC Number:
- 237-198-5
- EC Name:
- Desmedipham
- Cas Number:
- 13684-56-5
- Molecular formula:
- C16 H16 N2 O4
- IUPAC Name:
- ethyl 3´-phenylcarbamoyloxycarbanilate
- Test material form:
- solid: particulate/powder
- Details on test material:
- The test material is Desmedipham but the purity has not been specified.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Five male and 5 female nulliparous and non-pregnant young adult rats of the Sprague-Dawley strain were used. They were 8-10 weeks old and weighed 215-273 g at dosing. The rats were housed by sex in polypropylene cages with mesh floors suspended over absorbent paper lined trays with a maximum of 5 animals per cage. The rats were fed Rat and Mouse No. 1 Diet. Food and tap water were available ad libitum throughout the study. The diet and water are analysed on a regular basis and meet the laboratory's criteria. Mean environmental maximum and minimum temperatures were 21°C and 19°C and mean relative humidity was 50%. A 12 h light/dark cycle was in operation (light hours 0700-1900 h). The rats were allowed an acclimatisation period of 7 days before test commencement.
Administration / exposure
- Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- A group of 5 male and 5 female rats was prepared by clipping the backs free of hair, approximately 24 hours before application of the test material. Care was taken to avoid abrading the skin. Desmedipham was administered dermally in a single application under occlusion at a dose level of 2000 mg/kg bw. The test material was applied evenly onto a gauze dressing which was applied to the shaved back of each rat. At least 10% of the body surface was in contact with the test material. The trunk of the rat was then encircled with a strip of non-irritating tape. After a contact period of 24 hours following dosing the dressing was removed and the skin wiped with a water dampened tissue to remove excess test material.
- Duration of exposure:
- 24 hours
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Remarks:
- Not required for this study type
- Details on study design:
- - Duration of observation period following administration: 14 days.
- Frequency of observations and weighing: Observed daily. Weighed 3 times: prior to dosing, 7 days after dosing and 14 days after dosing.
- Necropsy of survivors performed: yes - Statistics:
- Not specified.
Results and discussion
Effect levels
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: no mortality observed at the limit dose of 2000 mg/kg bw
- Mortality:
- None
- Clinical signs:
- other: other:
- Body weight:
- other body weight observations
- Gross pathology:
- There were no effects of treatment
Any other information on results incl. tables
Table 1: Desmedipham: Acute Dermal Toxicity (Limit) Test in Rats, Test Results: Mortality
Animal/Sex | Mortality | Clinical signs | Necropsy findings |
11 (M) | 0/5 | NAD | NAD |
12 | NAD | NAD | |
13 | NAD | NAD | |
14 | NAD | NAD | |
15 | NAD | NAD | |
16 (F) | 0/5 | NAD | NAD |
17 | NAD | NAD | |
18 | NAD | NAD | |
19 | NAD | NAD | |
20 | NAD | NAD |
Table 2: Desmedipham: Acute Dermal Toxicity (Limit) Test in Rats, Test Results: Body weight
Animal/Sex | Body Weight (g) | |||
At Dosing | After 7 Days | After 14 Days | Gain (Loss) | |
11 (M) | 266 | 305 | 328 | 62 |
12 | 272 | 304 | 337 | 65 |
13 | 264 | 301 | 329 | 65 |
14 | 273 | 305 | 332 | 59 |
15 | 272 | 320 | 351 | 79 |
Mean | 269 | 307 | 335 | 66 |
± S.D. | 4 | 7 | 9 | 8 |
16 (F) | 215 | 229 | 229 | 14 |
17 | 236 | 252 | 276 | 40 |
18 | 253 | 260 | 290 | 37 |
19 | 238 | 260 | 280 | 42 |
20 | 224 | 241 | 249 | 25 |
Mean | 233 | 248 | 265 | 32 |
± S.D. | 14 | 13 | 25 | 12 |
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The acute dermal LD50 of desmedipham in the rat was found to be >2000 mg/kg bw under the conditions of this study. Desmedipham does not therefore require classification for acute dermal toxicity in any category according to the CLP criteria.
- Executive summary:
The acute dermal toxicity potential of Desmedipham, was investigated in rats. No deaths occurred and no clinical signs were noted after a 24 hour dermal administration, under occlusion, of Desmedipham at a dose level of 2000 mg/kg bw. No abnormalities were detected at necropsy. The acute dermal LD50 of desmedipham in the rat was found to be >2000 mg/kg bw under the conditions of this study. Desmedipham does not therefore require classification for acute dermal toxicity in any category according to the CLP criteria.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.